{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+first&page=22",
    "query": {
      "intervention": "Placebo first",
      "page": 22
    },
    "page_size": 10
  },
  "pagination": {
    "page": 22,
    "page_size": 10,
    "total_count": 3263,
    "total_pages": 327,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+first&page=23&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+first&page=21&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-14T23:45:07.732Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02382848",
      "title": "Effectiveness of Prazosin in Bulimic Patients Experiencing Nightmares Due to PTSD",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Stress Disorders, Post-Traumatic",
        "Bulimia Nervosa"
      ],
      "interventions": [
        {
          "name": "Prazosin",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Milton S. Hershey Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "45 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 45 Years · Female only"
      },
      "enrollment_count": 9,
      "start_date": "2015-07",
      "completion_date": "2018-03-09",
      "has_results": true,
      "last_update_posted_date": "2019-07-16",
      "last_synced_at": "2026-11-14T23:45:07.732Z",
      "location_count": 1,
      "location_summary": "Hershey, Pennsylvania",
      "locations": [
        {
          "city": "Hershey",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02382848"
    },
    {
      "nct_id": "NCT02535949",
      "title": "Tranexamic Acid Mechanisms and Pharmacokinetics in Traumatic Injury",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Hemorrhage",
        "Shock",
        "Wounds and Injuries"
      ],
      "interventions": [
        {
          "name": "Tranexamic Acid",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Washington University School of Medicine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 150,
      "start_date": "2016-02",
      "completion_date": "2017-07-07",
      "has_results": true,
      "last_update_posted_date": "2021-08-31",
      "last_synced_at": "2026-11-14T23:45:07.732Z",
      "location_count": 1,
      "location_summary": "St Louis, Missouri",
      "locations": [
        {
          "city": "St Louis",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02535949"
    },
    {
      "nct_id": "NCT00615940",
      "title": "Combination of Oral WX-671 Plus Capecitabine vs. Capecitabine Monotherapy in First-line Her2-negative Metastatic Breast Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Metastatic Breast Cancer"
      ],
      "interventions": [
        {
          "name": "WX-671",
          "type": "DRUG"
        },
        {
          "name": "placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Heidelberg Pharma AG",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 132,
      "start_date": "2008-07",
      "completion_date": "2012-04",
      "has_results": false,
      "last_update_posted_date": "2014-02-28",
      "last_synced_at": "2026-11-14T23:45:07.732Z",
      "location_count": 3,
      "location_summary": "New York, New York • Cleveland, Ohio • Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Cleveland",
          "state": "Ohio"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00615940"
    },
    {
      "nct_id": "NCT02325791",
      "title": "Study to Evaluate the Efficacy and Safety of Suptavumab (REGN2222) for the Prevention of Medically Attended RSV (Respiratory Syncytial Virus) Infection in Preterm Infants",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Respiratory Syncytial Virus Infections"
      ],
      "interventions": [
        {
          "name": "Suptavumab 30 mg/kg",
          "type": "DRUG"
        },
        {
          "name": "Placebo Matched to Suptavumab",
          "type": "DRUG"
        },
        {
          "name": "Suptavumab 30 mg/kg- 1 Dose",
          "type": "DRUG"
        },
        {
          "name": "Suptavumab 30 mg/kg - 2 Doses",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Regeneron Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "6 Months",
        "sex": "ALL",
        "summary": "Up to 6 Months"
      },
      "enrollment_count": 1177,
      "start_date": "2015-07-21",
      "completion_date": "2017-09-26",
      "has_results": true,
      "last_update_posted_date": "2018-11-06",
      "last_synced_at": "2026-11-14T23:45:07.732Z",
      "location_count": 107,
      "location_summary": "Birmingham, Alabama • Mobile, Alabama • Little Rock, Arkansas + 104 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "Bell Gardens",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02325791"
    },
    {
      "nct_id": "NCT03504397",
      "title": "A Study to Compare Zolbetuximab (IMAB362) and Chemotherapy With Placebo and Chemotherapy in Adults With Gastric Cancer.",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer",
        "Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer",
        "Metastatic Gastric Adenocarcinoma or Cancer",
        "Metastatic Gastroesophageal Junction (GEJ) Adenocarcinoma"
      ],
      "interventions": [
        {
          "name": "zolbetuximab",
          "type": "DRUG"
        },
        {
          "name": "placebo",
          "type": "DRUG"
        },
        {
          "name": "oxaliplatin",
          "type": "DRUG"
        },
        {
          "name": "folinic acid",
          "type": "DRUG"
        },
        {
          "name": "fluorouracil",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Astellas Pharma Global Development, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 565,
      "start_date": "2018-06-21",
      "completion_date": "2027-03-31",
      "has_results": true,
      "last_update_posted_date": "2026-10-20",
      "last_synced_at": "2026-11-14T23:45:07.732Z",
      "location_count": 51,
      "location_summary": "Phoenix, Arizona • Tucson, Arizona • Bakersfield, California + 42 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Bakersfield",
          "state": "California"
        },
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Fullerton",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03504397"
    },
    {
      "nct_id": "NCT04128696",
      "title": "Study of GSK3359609 and Pembrolizumab in Programmed Death Receptor 1-ligand 1 (PD-L1) Positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Neoplasms, Head and Neck"
      ],
      "interventions": [
        {
          "name": "feladilimab",
          "type": "DRUG"
        },
        {
          "name": "Pembrolizumab",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 315,
      "start_date": "2019-11-21",
      "completion_date": "2023-06-20",
      "has_results": true,
      "last_update_posted_date": "2024-07-10",
      "last_synced_at": "2026-11-14T23:45:07.732Z",
      "location_count": 13,
      "location_summary": "Duarte, California • Washington D.C., District of Columbia • St. Petersburg, Florida + 10 more",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "St. Petersburg",
          "state": "Florida"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04128696"
    },
    {
      "nct_id": "NCT04730050",
      "title": "A Phase I Clinical Trial to Investigate the Safety, Tolerability, and Pharmacokinetic Characteristics of TT-01025-CL in Healthy Subjects",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "TT-01025-CL",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "LG Chem",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 64,
      "start_date": "2021-02-17",
      "completion_date": "2021-12",
      "has_results": false,
      "last_update_posted_date": "2021-11-24",
      "last_synced_at": "2026-11-14T23:45:07.732Z",
      "location_count": 1,
      "location_summary": "Las Vegas, Nevada",
      "locations": [
        {
          "city": "Las Vegas",
          "state": "Nevada"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04730050"
    },
    {
      "nct_id": "NCT01169103",
      "title": "Effect of Recombinant Human Growth Hormone (rhGH) on Abdominal Fat and Cardiovascular Risk in Obese Girls",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Obesity"
      ],
      "interventions": [
        {
          "name": "recombinant human growth hormone (rhGH)",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Massachusetts General Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "13 Years",
        "maximum_age": "21 Years",
        "sex": "FEMALE",
        "summary": "13 Years to 21 Years · Female only"
      },
      "enrollment_count": 22,
      "start_date": "2010-03",
      "completion_date": "2014-12",
      "has_results": true,
      "last_update_posted_date": "2021-11-02",
      "last_synced_at": "2026-11-14T23:45:07.732Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01169103"
    },
    {
      "nct_id": "NCT01002742",
      "title": "Acute Graft-versus-Host Disease Treatment (BMT CTN 0802)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Graft-versus-Host Disease",
        "Immune System Disorders"
      ],
      "interventions": [
        {
          "name": "Mycophenolate Mofetil",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Medical College of Wisconsin",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 236,
      "start_date": "2010-01",
      "completion_date": "2013-06",
      "has_results": true,
      "last_update_posted_date": "2023-01-04",
      "last_synced_at": "2026-11-14T23:45:07.732Z",
      "location_count": 36,
      "location_summary": "Duarte, California • La Jolla, California • Stanford, California + 28 more",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Stanford",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Gainesville",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01002742"
    },
    {
      "nct_id": "NCT02763579",
      "title": "A Study of Carboplatin Plus Etoposide With or Without Atezolizumab in Participants With Untreated Extensive-Stage (ES) Small Cell Lung Cancer (SCLC)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Small Cell Lung Carcinoma"
      ],
      "interventions": [
        {
          "name": "Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody",
          "type": "DRUG"
        },
        {
          "name": "Carboplatin",
          "type": "DRUG"
        },
        {
          "name": "Etoposide",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Hoffmann-La Roche",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 503,
      "start_date": "2016-06-07",
      "completion_date": "2022-07-07",
      "has_results": true,
      "last_update_posted_date": "2023-07-28",
      "last_synced_at": "2026-11-14T23:45:07.732Z",
      "location_count": 22,
      "location_summary": "Fort Myers, Florida • Orlando, Florida • St. Petersburg, Florida + 18 more",
      "locations": [
        {
          "city": "Fort Myers",
          "state": "Florida"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        },
        {
          "city": "St. Petersburg",
          "state": "Florida"
        },
        {
          "city": "Marietta",
          "state": "Georgia"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02763579"
    }
  ]
}